Andrew J. Carroll spends much of his time researching Internal medicine, Leukemia, Oncology, Myeloid leukemia and Cancer. His research in Internal medicine intersects with topics in Gastroenterology, CEBPA and Cytogenetics. His study with Leukemia involves better knowledge in Immunology.
He interconnects Regimen, Pathology, Gene mutation, Antimetabolite and Minimal residual disease in the investigation of issues within Oncology. His study in Myeloid leukemia is interdisciplinary in nature, drawing from both Hazard ratio, Surgery, Bone marrow and Core binding factor acute myeloid leukemia. His Cancer study incorporates themes from Proportional hazards model and Risk factor.
His main research concerns Internal medicine, Oncology, Leukemia, Myeloid leukemia and Immunology. His Gastroenterology research extends to Internal medicine, which is thematically connected. Andrew J. Carroll works mostly in the field of Oncology, limiting it down to concerns involving Cytogenetics and, occasionally, Karyotype and Trisomy.
His Leukemia study combines topics in areas such as Myeloid, BAALC, NPM1 and Chromosomal translocation. His Myeloid leukemia research integrates issues from Survival analysis, Gene and Transplantation. The study incorporates disciplines such as Group B and Risk factor in addition to Cancer.
His primary areas of investigation include Internal medicine, Oncology, Myeloid leukemia, Leukemia and Cancer. His work in Minimal residual disease, Hematopoietic stem cell transplantation, Chemotherapy regimen, Acute lymphocytic leukemia and Survival rate are all subfields of Internal medicine research. His Chemotherapy regimen research is multidisciplinary, relying on both Cytarabine and Mutation.
His work deals with themes such as Clinical trial, Chemotherapy, Standard Risk and Lymphoblastic Leukemia, which intersect with Oncology. His Myeloid leukemia research is multidisciplinary, incorporating perspectives in Gene, NPM1 and Gene mutation. To a larger extent, he studies Immunology with the aim of understanding Leukemia.
His scientific interests lie mostly in Internal medicine, Oncology, Leukemia, Myeloid leukemia and Survival rate. His study in Cancer, Hematopoietic stem cell transplantation, Retrospective cohort study, Minimal residual disease and Dasatinib is carried out as part of his Internal medicine studies. His Oncology study combines topics from a wide range of disciplines, such as B-cell acute lymphoblastic leukemia, Clinical trial, Hypodiploid Acute Lymphoblastic Leukemia, Chemotherapy and Young adult.
His research investigates the connection between Chemotherapy and topics such as MCL1 that intersect with issues in Cancer research. His research investigates the connection between Leukemia and topics such as Haematopoiesis that intersect with problems in Hematology, T and Lymphoma. His research on Myeloid leukemia concerns the broader Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll.
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
M Smith;D Arthur;B Camitta;A J Carroll.
Journal of Clinical Oncology (1996)
Absence of the Wild-Type Allele Predicts Poor Prognosis in Adult de Novo Acute Myeloid Leukemia with Normal Cytogenetics and the Internal Tandem Duplication of FLT3 A Cancer and Leukemia Group B Study
Susan P. Whitman;Kellie J. Archer;Lan Feng;Claudia Baldus.
Cancer Research (2001)
Frequency of Prolonged Remission Duration after High-Dose Cytarabine Intensification in Acute Myeloid Leukemia Varies by Cytogenetic Subtype
Clara D. Bloomfield;David Lawrence;John C. Byrd;Andrew Carroll.
Cancer Research (1998)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Michael J. Borowitz;Meenakshi Devidas;Stephen P. Hunger;W. Paul Bowman;W. Paul Bowman.
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
Kirk R. Schultz;W. Paul Bowman;Alexander Aledo;William B. Slayton.
Journal of Clinical Oncology (2009)
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Linda Holmfeldt;Lei Wei;Ernesto Diaz-Flores;Michael Walsh.
Nature Genetics (2013)
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
Yu Liu;John Easton;Ying Shao;Jamie Maciaszek.
Nature Genetics (2017)
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
Kirk R. Schultz;D. Jeanette Pullen;Harland N. Sather;Jonathan J. Shuster.
MicroRNA expression in cytogenetically normal acute myeloid leukemia
Guido Marcucci;Michael D. Radmacher;Michael D. Radmacher;Kati Maharry;Kati Maharry;Krzysztof Mrózek.
The New England Journal of Medicine (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: